comparemela.com

Latest Breaking News On - Ambrx biopharma - Page 1 : comparemela.com

J&J gains another bispecific antibody with $1.25B skin drug buy

BioPharma

Jersey
Switzerland
Swiss
Abbvie-rinvoq
Regeneron-dupixent
Ambrx-biopharma
Johnson
Novo-holdings
Boehringer-ingelheim
Dive-brief
Yellow-jersey-therapeutics
Candice-long

J&J scratches AD itch by acquiring experimental eczema antibody for $1.25B

J&J will pick up Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab Therapeutics, for $1.25 billion to acquire all assets related to NM26.

Jersey
David-urech
David-lee
Ambrx-biopharma
Johnson
Drug-administration
Johnson-innovative-medicine
Yellow-jersey-therapeutics
Numab-therapeutics

Johnson & Johnson plans $850M Proteologix acquisition

The play for the California biotech will expand the company's dermatology portfolio.

La-jolla
California
United-states
David-lee
David-shen
Ambrx-biopharma
Johnson
Proteologix-inc
New-brunswick-based

Biopharma M&A surges year over year in Q1

M&amp;amp;amp;A dealmaking in the pharmaceutical and biotechnology industry is on the rise, signaling increased confidence and a focus on growth amid challenges. Read more here.

Denmark
Danish
Alison-labya
Ambrx-biopharma
Novo-holding
Fusion-pharmaceuticals
Novo-nordisk
Gilead-science
Cymabay-therapeutics
Data-business-fundamentals-analyst-alison-labya
Inflation-reduction-act
Biopharmaceutical-industry

Biopharma M&A activity jumped 71% in Q1 2024

Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking.

Alison-labya
Ambrx-biopharma
Astrazeneca
Johnson
Novo-holdings
Gilead-sciences
Fusion-pharmaceuticals
Novartis
Novo-nordisk
Big-pharma
Inflation-reduction-act
Novo-holdings

vimarsana © 2020. All Rights Reserved.